Nanoparticle Uptake Pathways in Human Corneal Epithelial Cel
2026-06-15
Understanding Nanoparticle Uptake in the Human Corneal Epithelium
Study Background and Research Question
Topical drug delivery for ocular diseases remains a major clinical challenge due to the formidable barriers presented by the tear film and the multilayered corneal epithelium. Although topical formulations are widely used, their bioavailability is limited by rapid clearance, low tissue penetration, and the complex, protective structure of the ocular surface. Polymeric nanoparticles—particularly those based on poly(lactic-co-glycolic acid) (PLGA)—have emerged as promising carriers for enhancing drug residence time and penetration. However, the mechanisms by which nanoparticle physicochemical properties (size, surface chemistry) direct their uptake by human corneal epithelial cells (HCECs) are not fully understood. The reference study (Azadi & David, 2024) addresses this gap, aiming to clarify how nanoparticle design influences cellular internalization pathways and, ultimately, ocular drug delivery efficiency.Key Innovation from the Reference Study
Previous work had established the ability of nanoparticles to traverse ocular barriers, but lacked detailed mechanistic insights into the uptake process at the cellular level. The reference paper's innovation lies in its direct comparison of PLGA nanoparticles differing in size and surface modifications (alginate, chitosan, PEG) to systematically dissect their interactions with HCECs. By integrating an in vitro HCEC monolayer with a simulated mucosal environment, the authors closely mimic the human corneal barrier and provide quantitative evidence for the dominant internalization pathways. The study’s use of selective endocytic inhibitors allows precise attribution of uptake to distinct cellular processes, moving beyond descriptive uptake studies to mechanistic delineation.Methods and Experimental Design Insights
The authors synthesized monodisperse PLGA nanoparticles (PDI < 0.2) with diameters ranging from 100 to 250 nm and zeta potentials between –25 and +15 mV. Surface modifications included mucoadhesive polymers (alginate and chitosan) and the mucopenetrative polymer PEG. Nanoparticles were characterized for size, charge, and morphology. Cytotoxicity was assessed via the MTT assay, confirming that concentrations up to 100 μg/mL yielded high viability (70–100%) after 24 hours, indicating suitability for biological assays. Cellular uptake was quantified using an in vitro HCEC monolayer model exposed to simulated mucosal solution, closely replicating the ocular surface environment. To dissect uptake mechanisms, the researchers employed chemical inhibitors specific for macropinocytosis, caveolae-mediated endocytosis, clathrin-mediated endocytosis, and phagocytosis. This approach enabled attribution of nanoparticle internalization to specific endocytic routes based on changes in uptake upon inhibitor treatment (Azadi & David, 2024).Core Findings and Why They Matter
The study’s principal finding is that energy-dependent endocytosis is the dominant uptake mechanism for PLGA nanoparticles in HCECs. Specifically, macropinocytosis and caveolae-mediated endocytosis account for the majority of nanoparticle internalization, while clathrin-mediated endocytosis plays a secondary role. Phagocytosis was not implicated, consistent with the size range and surface chemistry of the nanoparticles tested. Nanoparticle size and surface characteristics critically influence uptake efficiency. The 100 nm PLGA nanoparticles and PEG-modified 150 nm particles exhibited the highest cellular uptake, suggesting an optimal size and surface property window for maximizing delivery to the corneal epithelium. This mechanistic insight has direct implications for the rational design of ocular drug delivery systems: by tailoring nanoparticle dimensions and surface polymers, researchers can optimize penetration through both the mucous layer and the densely packed epithelial cells, thereby enhancing drug bioavailability without compromising cell viability. These findings build on the broader literature demonstrating the importance of actin cytoskeleton dynamics in endocytic processes. It is well established that inhibitors of actin polymerization, such as Cytochalasin D, can block energy-dependent endocytosis, confirming the mechanistic dependence of nanoparticle internalization on cytoskeletal remodeling (internal article).Comparison with Existing Internal Articles
Internal resources such as "Nanoparticle Uptake in Corneal Cells: Role of Physicochemical Properties" and "Nanoparticle Uptake Mechanisms in Human Corneal Epithelial Cells" reinforce the core message of the reference study: macropinocytosis and caveolae-mediated endocytosis are the dominant uptake routes for nanoparticles in HCECs, and both are sensitive to changes in size and surface charge. These findings are in agreement with the comprehensive mechanistic assessment in the reference paper, providing a consistent cross-validation across independent studies (Nanoparticle Uptake in Corneal Cells). Complementary resources focused on Cytochalasin D, such as "Cytochalasin D (SKU B6645): Reliable Actin Polymerization Inhibition," offer practical guidance for experimental design in cellular uptake research. These articles highlight Cytochalasin D's role as a potent actin polymerization inhibitor, capable of blocking endocytic processes—including those identified as central in the reference study—thereby enabling researchers to dissect the contributions of actin-dependent mechanisms (Cytochalasin D in Applied Actin Polymerization Inhibition Workflows).Limitations and Transferability
While the study provides valuable mechanistic insights, certain limitations should be acknowledged. The in vitro HCEC model, though highly relevant, cannot fully recapitulate the complexity of in vivo ocular barriers, including tear dynamics and immune factors. Furthermore, the study focused on a specific range of nanoparticle sizes and chemistries, so extrapolation to other materials or larger/smaller particles should be done cautiously. The use of chemical inhibitors, while informative, may have off-target effects that complicate interpretation. These caveats highlight the need for further validation in ex vivo and in vivo settings. The transferability of these findings to other epithelial or mucosal systems is plausible, given the conserved nature of endocytic pathways and cytoskeletal regulation, but should be empirically tested. Notably, the role of actin polymerization in mediating macropinocytosis and caveolae-mediated uptake appears robust across multiple cell types, as supported by both the referenced and internal literature.Protocol Parameters
- Nanoparticle preparation: Use PLGA nanoparticles with sizes in the 100–150 nm range and test surface modifications (e.g., PEG, alginate, chitosan) for optimal uptake.
- Cell model: Employ a confluent HCEC monolayer integrated with simulated mucosal solution to mimic the corneal barrier.
- Cytotoxicity testing: Assess nanoparticle concentrations up to 100 μg/mL for 24 h to ensure cell viability remains >70% (reference study).
- Uptake inhibition studies: Apply pathway-specific chemical inhibitors (e.g., for macropinocytosis, caveolae-mediated endocytosis, clathrin-mediated endocytosis) to dissect uptake mechanisms.
- Actin polymerization assays: Consider using Cytochalasin D at 0.2–0.5 μg/mL for 1–2 hours to selectively inhibit actin-dependent processes (product information).